Literature DB >> 7826913

Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia.

R Rodriguez1, M Machiavelli, B Leone, A Romero, M A Cuevas, M Langhi, L Romero Acuña, J Romero Acuña, S Amato, M Barbieri.   

Abstract

BACKGROUND: Minoxidil (Mx) is known to induce hair growth in men with male-pattern baldness. Based on this potential, the effectiveness of Mx 2% topical solution was evaluated in cancer patients (pts) to prevent doxorubicin-induced alopecia. PATIENTS AND METHODS: 48 female pts with different types of solid tumors treated with doxorubicin-based chemotherapy in a dose range of 50-60 mg/m2/cycle were randomly assigned to receive Mx 2% topical solution or placebo.
RESULTS: 88% and 92% of pts in both arms showed severe alopecia (p = ns). No adverse effects were observed.
CONCLUSION: In this study Mx 2% topical solution was non-toxic but was not effective in the prevention of chemotherapy-induced alopecia.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7826913     DOI： 10.1093/oxfordjournals.annonc.a058986

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  11 in total

Review 1.  Protection against chemotherapy-induced alopecia.

Authors:  Jie Wang; Ze Lu; Jessie L-S Au
Journal:  Pharm Res       Date:  2006-11       Impact factor: 4.200

Review 2.  [Skin changes with chemotherapy].

Authors:  A L Branzan; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

3.  Laminin-511, inducer of hair growth, is down-regulated and its suppressor in hair growth, laminin-332 up-regulated in chemotherapy-induced alopecia.

Authors:  Hisayoshi Imanishi; Daisuke Tsuruta; Chiharu Tateishi; Koji Sugawara; Ralf Paus; Tsutomu Tsuji; Masamitsu Ishii; Kazuo Ikeda; Hiroyuki Kunimoto; Koichi Nakajima; Jonathan C R Jones; Hiromi Kobayashi
Journal:  J Dermatol Sci       Date:  2010-02-16       Impact factor: 4.563

Review 4.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

Review 5.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

Review 6.  Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.

Authors:  Paul J Hesketh; Diane Batchelor; Mitch Golant; Gary H Lyman; Nelson Rhodes; Denise Yardley
Journal:  Support Care Cancer       Date:  2004-06-19       Impact factor: 3.603

7.  A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia.

Authors:  Rohit Joshi; Ian Olver; Dorothy Keefe; Toni Marafioti; Keith Smith
Journal:  Support Care Cancer       Date:  2007-05-22       Impact factor: 3.603

Review 8.  Prevention and Treatment of Chemotherapy-Induced Alopecia.

Authors:  Alfredo Rossi; Gemma Caro; Maria Caterina Fortuna; Flavia Pigliacelli; Andrea D'Arino; Marta Carlesimo
Journal:  Dermatol Pract Concept       Date:  2020-06-29

9.  A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients.

Authors:  Suyoun Chung; Siew-Kee Low; Hitoshi Zembutsu; Atsushi Takahashi; Michiaki Kubo; Mitsunori Sasa; Yusuke Nakamura
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

Review 10.  Minoxidil and its use in hair disorders: a review.

Authors:  Poonkiat Suchonwanit; Sasima Thammarucha; Kanchana Leerunyakul
Journal:  Drug Des Devel Ther       Date:  2019-08-09       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.